Skip to main content
Premium Trial:

Request an Annual Quote

IBM Signs Partners to Accelerate Cancer Research

NEW YORK, Nov. 8 (GenomeWeb News) - IBM has signed separate agreements with a number of research centers to accelerate cancer research, diagnosis and treatment, the company said today.

 

The agreements were signed with Memorial Sloan-Kettering Cancer Center, the Molecular Profiling Institute, and the CHU Sainte-Justine Research Center- Mother and Child University Hospital Center.

 

IBM and Sloan-Kettering will build a system to study long-term cancer-related illnesses, identify disease trends, and determine success rates. With a $3 million technology grant from IBM, Sloan-Kettering will also integrate its hospital data and create a searchable database for pathology reports.

 

IBM and Molecular Profiling will jointly develop diagnostic technology. Advances from Molecular Profiling's partnership with Translational Genomics Research Institute will be shared with IBM, the company said.

 

IBM and CHU, a teaching hospital affiliated with the University of Montreal, will build a system based on IBM's Clinical Genomics Solution to define the genetic markers for acute lymphoblastic leukemia.

 

Financial details were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.